Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Soleil Boughton sold 25,111 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total transaction of $691,808.05. Following the completion of the sale, the insider owned 313,964 shares in the company, valued at $8,649,708.20. This represents a 7.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Hims & Hers Health Stock Up 5.7%
Hims & Hers Health stock opened at $33.67 on Friday. The firm has a market capitalization of $7.86 billion, a price-to-earnings ratio of -53.44 and a beta of 2.40. The company’s 50 day simple moving average is $32.37 and its 200 day simple moving average is $26.14. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.17 EPS. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post -0.05 EPS for the current year.
Key Headlines Impacting Hims & Hers Health
- Positive Sentiment: Analysts and investors see continued expansion opportunities in branded GLP-1 weight-loss products, testosterone, peptides, international markets and AI-driven patient support. These initiatives could strengthen revenue growth and improve operating efficiency over time. What is driving HIMS stock’s rally
- Positive Sentiment: Barclays maintained an “overweight” rating, indicating a favorable long-term view even after reducing its price target from $39 to $35. The revised target remains above the referenced trading level. Barclays price-target update
- Neutral Sentiment: Recent insider sales by CFO Oluyemi Okupe and other executives were made under pre-arranged Rule 10b5-1 plans. While the transactions may create a modest overhang, the insiders continued to hold sizable positions, reducing the signal that management confidence has materially weakened. HIMS insider sales
- Neutral Sentiment: Analyst views remain divided. Needham raised its price target to $42 and kept a Buy rating, while the broader consensus remains Hold, reflecting strong revenue growth but uncertainty around margins and the GLP-1 strategy.
- Negative Sentiment: Three law firms announced investigations into potential securities-law violations. These announcements are investor outreach notices—not findings of wrongdoing—but they add legal, compliance and reputational risk amid scrutiny of privacy practices, billing and subscription cancellations. Kaplan Fox investigation
- Negative Sentiment: The latest quarterly results showed revenue of $753.2 million, up 38.2% year over year and above expectations, but the company reported a $0.37-per-share loss versus the expected $0.05 loss. Persistent losses and weak profitability could limit further upside unless margins improve.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on HIMS. Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a research note on Friday, August 7th. UBS Group set a $23.00 price target on Hims & Hers Health in a research report on Friday, May 22nd. Morgan Stanley lifted their price objective on Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a report on Tuesday, August 11th. Jefferies Financial Group set a $24.50 price objective on Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Citigroup lowered their target price on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $32.17.
Check Out Our Latest Report on Hims & Hers Health
Hedge Funds Weigh In On Hims & Hers Health
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Concurrent Investment Advisors LLC raised its stake in shares of Hims & Hers Health by 109.8% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 35,272 shares of the company’s stock valued at $1,223,000 after purchasing an additional 18,459 shares during the period. Nykredit A S bought a new stake in shares of Hims & Hers Health in the second quarter valued at about $222,000. B. Metzler seel. Sohn & Co. AG acquired a new position in shares of Hims & Hers Health during the second quarter worth about $2,992,000. Resolute Advisors LLC acquired a new position in shares of Hims & Hers Health during the second quarter worth about $322,000. Finally, QV Investors Inc. bought a new position in shares of Hims & Hers Health during the second quarter worth about $7,771,000. 63.52% of the stock is owned by institutional investors and hedge funds.
About Hims & Hers Health
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Read More
- Five stocks we like better than Hims & Hers Health
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
